Literature DB >> 32392332

Hydroxychloroquine in Coronavirus Disease 2019 Patients: What Still Needs to Be Known About the Kinetics.

Guillaume Martin-Blondel1, Stéphanie Ruiz2, Marlène Murris3, Stanilas Faguer4, Véronigue Duhalde5, Frédéric Eyvrard5, Jacques Izopet6, Jean-Michel Mansuy6, Yves Rolland7, Karen Delavigne8, Rosine Guimbaud9, Grégory Pugnet10, Jean-Marie Conil2, Bernard Georges2, Pierre Delobel1, Vincent Minville2, Stein Silva Sifontes11, Didier Concordet12, Peggy Gandia12,13.   

Abstract

Different dosage regimens of hydroxychloroquine are used to manage coronavirus disease 2019 (COVID-19) patients, without information on the pharmacokinetics in this population. Blood samples (n = 101) were collected from 57 COVID-19 patients for 7 days, and concentrations were compared with simulated kinetic profiles. Hydroxychloroquine exposure is low and cannot be predicted by other populations.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  COVID-19; dosage regimens; drug monitoring; hydroxychloroquine; population pharmacokinetic modeling

Mesh：

Substances：

Year:  2020        PMID： 32392332      PMCID： PMC7239205          DOI： 10.1093/cid/ciaa558

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  6 in total

1.  Dose Optimization of Hydroxychloroquine for Coronavirus Infection 2019: Do Blood Concentrations Matter?

Authors:  Matthew M Ippolito; Charles Flexner
Journal:  Clin Infect Dis       Date:  2020-12-31       Impact factor: 9.079

2.  Development and Validation of a Simple and Rapid Ultrahigh-Performance Liquid Chromatography Tandem Spectrometry Method for the Quantification of Hydroxychloroquine in Plasma and Blood Samples in the Emergency Context of SARS-CoV-2 Pandemic.

Authors:  Natalia Doudka; Madeleine Giocanti; Manon Basso; Renée Ugdonne; Karine Barthelemy; Bruno Lacarelle; Olivier Blin; Caroline Solas; Romain Guilhaumou
Journal:  Ther Drug Monit       Date:  2021-08-01       Impact factor: 3.681

3.  Hydroxychloroquine lung pharmacokinetics in critically ill patients infected with COVID-19.

Authors:  S Ruiz; D Concordet; T Lanot; B Georges; P Goudy; S Baklouti; C Mane; E Losha; H Vinour; D Rousset; M Lavit; V Minville; J-M Conil; P Gandia
Journal:  Int J Antimicrob Agents       Date:  2020-11-28       Impact factor: 5.283

4.  Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations.

Authors:  Manuel Battegay; Parham Sendi; Catia Marzolini; Felix Stader; Marcel Stoeckle; Fabian Franzeck; Adrian Egli; Stefano Bassetti; Alexa Hollinger; Michael Osthoff; Maja Weisser; Caroline E Gebhard; Veronika Baettig; Julia Geenen; Nina Khanna; Sarah Tschudin-Sutter; Daniel Mueller; Hans H Hirsch
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

Review 5.  Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection.

Authors:  Nicolas Venisse; Gilles Peytavin; Stephane Bouchet; Marie-Claude Gagnieu; Rodolphe Garraffo; Romain Guilhaumou; Caroline Solas
Journal:  Antiviral Res       Date:  2020-07-10       Impact factor: 5.970

6.  Population Pharmacokinetics of Hydroxychloroquine in COVID-19 Patients: Implications for Dose Optimization.

Authors:  Pauline Thémans; Leila Belkhir; Nicolas Dauby; Jean-Cyr Yombi; Julien De Greef; Kevin-Alexandre Delongie; Martin Vandeputte; Rakan Nasreddine; Xavier Wittebole; Francoise Wuillaume; Cécile Lescrainier; Veerle Verlinden; Sophie Kiridis; Jean-Michel Dogné; Jamila Hamdani; Pierre Wallemacq; Flora T Musuamba
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2020-12       Impact factor: 2.441
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.